Mehdi Tafti - NLS Pharmaceutics Interim Officer
| NLSPW Stock | USD 0.01 0 11.11% |
Insider
Mehdi Tafti is Interim Officer of NLS Pharmaceutics AG
| Age | 65 |
| Address | The Circle 6, Zurich, Switzerland, 8058 |
| Phone | 41 44 512 21 50 |
| Web | https://nlspharma.com |
NLS Pharmaceutics Management Efficiency
The company has return on total asset (ROA) of (2.2776) % which means that it has lost $2.2776 on every $100 spent on assets. This is way below average. NLS Pharmaceutics' management efficiency ratios could be used to measure how well NLS Pharmaceutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NLS Pharmaceutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.45 in 2024, whereas Return On Tangible Assets are likely to drop (6.92) in 2024. At this time, NLS Pharmaceutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 960.5 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 16 K in 2024.Similar Executives
| Found 9 records | INSIDER Age | ||
| Mark Newman | GeoVax Labs | 69 | |
| Chad MBA | NLS Pharmaceutics AG | N/A | |
| Harriet Robinson | GeoVax Labs | 86 | |
| CPA CPA | GeoVax Labs | 62 | |
| Sharon Keys | NLS Pharmaceutics AG | N/A | |
| iur LLM | NLS Pharmaceutics AG | 58 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Marc Cantillon | Reviva Pharmaceuticals Holdings | 66 | |
Management Performance
| Return On Asset | -2.28 |
NLS Pharmaceutics Leadership Team
Elected by the shareholders, the NLS Pharmaceutics' board of directors comprises two types of representatives: NLS Pharmaceutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NLS. The board's role is to monitor NLS Pharmaceutics' management team and ensure that shareholders' interests are well served. NLS Pharmaceutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NLS Pharmaceutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA IV, Interim Officer | ||
| Dr LLM, G Counsel | ||
| MA MBA, Interim Officer | ||
| Silvia Panigone, Interim Officer | ||
| Sandy MD, Interim Officer | ||
| Sharon Keys, Head Affairs | ||
| Geert MD, Interim Officer | ||
| iur LLM, General Counsel | ||
| Alexander Zwyer, CEO CoFounder | ||
| Eric MD, CoFounder Officer | ||
| Elena ThyenPighin, Chief Officer | ||
| Alexander MBA, CEO President | ||
| Mehdi Tafti, Interim Officer | ||
| George MD, Chief Development |
NLS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NLS Pharmaceutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -2.28 | ||||
| Number Of Shares Shorted | 24.07 K | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) | ||||
| Cash And Equivalents | 145.4 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.63 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.